Tachyon Ventures

Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.

TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.

Peptilogics is developing eCAP technology, a propriety platform with preclinical effectiveness against resistant bacteria and biofilms. The company is dedicated to developing a new class of broad-spectrum antibiotics to address the epidemic of multidrug-resistant bacterial infections. Peptilogics is a preclinical biotechnology company with demonstrated preclinical in vitro and in vivo effectiness against the priority resistant pathogens.

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, founded in 2013, that focuses on developing innovative solutions for bone reconstruction. The company employs advanced technology to create defect-specific living bone grafts by utilizing scans of a patient’s bone defect along with their own stem cells. This process involves cultivating the graft in a custom bioreactor, allowing the new bone to grow in a controlled environment. EpiBone's approach aims to deliver precise repair of bone defects, streamline surgical procedures, enhance bone formation and regeneration, and reduce recovery times. This technology presents a significant advancement for the over 900,000 patients who undergo bone-related surgeries annually, eliminating the complications typically associated with foreign body implants.